FDA Issues Warning Letter to Abbott Labs Over Infant Probiotic Marketing

The FDA has issued a warning letter to Illinois drugmaker Abbott Laboratories regarding its Similac Probiotic Tri-Blend for infants, over marketing claims that render the product an unapproved new drug and unlicensed biological product, and followed up with a general notice of its concerns about the use of probiotics on preterm infants on Thursday.
Source: Drug Industry Daily